PharmiWeb.com - Global Pharma News & Resources
28-Jan-2019

Global $5.7 Billion Hepatitis C Drugs Market Forecast, 2019-2023 - Led by AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, and Merck - ResearchAndMarkets.com

The "Global Hepatitis C Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The hepatitis C drugs market to register a revenue of around USD 5.7 billion by 2023.

The increasing number of voluntary licensing agreements to drive market growth

Voluntary licensing helps in improving access to essential medicines. Under the voluntary licensing agreement, patent holders license others to manufacture, import, and/or distribute their patented drugs. Voluntary licenses enable the development of generic versions of drugs, which increases the affordability and access to the patients.

Increasing demand for direct-acting antiviral

Direct-acting antiviral drugs have emerged as a curative option for patients with hepatitis C. These drugs act and block specific steps in the lifecycle of the HCV. They are known to target the specific nonstructural proteins of the virus that results in the disruption of viral replication. Thus, they show comparatively fewer side effects than the interferons, which were employed until the advent of direct-acting antiviral drugs.

Side effects of available drugs

The interferons indicated for the treatment of hepatitis C are known to be associated with harmful side effects such as excessive fatigue, headache, weight loss, alopecia, autoimmune disorders, high blood pressure, slowed growth in children, changes in vision, and malfunctioning of the lungs, liver, and pancreas. Due to these side effects, the interferon therapy is replaced by direct-acting antivirals at present.

Key Players

  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • Merck

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

PART 06: FIVE FORCES ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Acute hepatitis C
  • Chronic hepatitis C

PART 10: GEOGRAPHIC LANDSCAPE

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • Merck

For more information about this report visit https://www.researchandmarkets.com/research/9vs8zx/global_5_7?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005544/en/

Editor Details

Last Updated: 28-Jan-2019